In a Senate hearing, Sen. Bernie Sanders addressed the US pricing of Wegovy, highlighting the moral implications of the exorbitant costs compared to international prices.
Yale epidemiologists suggest that increasing access to GLP-1 weight-loss drugs could prevent over 42,000 deaths annually in the US due to obesity-related issues.
With over half of adults in China classified as overweight or obese, the demand for affordable weight-loss therapies like Wegovy is on the rise.
Despite the significantly lower pricing of Wegovy in China, the drug remains out of reach for many since it is not covered by national health insurance.
Collection
[
|
...
]